Translational Cancer Genomics and Proteomics
Overview
The overall aim of the section of Translational Cancer Genomics & Proteomics is to investigate the cell biological and genetic factors involved in the development of sporadic and hereditary breast and ovarian cancer, to investigate the processes of tumor progression and treatment failure, and to come to tailored treatments (for subgroups of patients) that are based on risk factors and cell biological phenotypes of individual tumors and circulating tumor cells. To carry out our research programs involving clinical, translational and mechanistic genomics and proteomics studies on sporadic and hereditary cancer our laboratories have available a database on over 3,000 families with familial and hereditary breast cancer, breast and ovarian tissue (>15,000 samples stored in liquid nitrogen) and serum banks (>50,000 samples), 60 well-characterized breast and ovarian cancer cell lines, and various metastasizing and non-metastasizing rat and mouse tumor models. In our clinic, phase I, II and III trails with various (targeted) drugs are performed.
The research is carried out in 4 different, but extensively collaborating, research groups:
- Breast Cancer Genomics & Proteomics (PI: dr. J.W.M. Martens)
- Integrated Genomics of Breast and Ovarian Cancer (PI: dr. P.M.J.J. Berns)
- Hereditary Cancer Syndromes (PI: dr. C. Seynaeve)
- Clinical Tumor Immunology (PI: dr. J.W. Gratama)